本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

諾瓦瓦克斯醫藥

8.38
-0.1400-1.64%
盤後8.36-0.0200-0.24%19:59 EDT
成交量:266.06萬
成交額:2,239.12萬
市值:13.61億
市盈率:3.29
高:8.58
開:8.50
低:8.28
收:8.52
52周最高:11.55
52周最低:5.01
股本:1.62億
流通股本:1.37億
量比:0.91
換手率:1.95%
股息:- -
股息率:- -
每股收益(TTM):2.54
每股收益(LYR):-1.2320
淨資產收益率:-898.20%
總資產收益率:14.52%
市淨率:36.18
市盈率(LYR):-6.80

資料載入中...

2024/08/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/20

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/06/18

關聯方擬減持公告

Form144|諾瓦瓦克斯公司董事James F.Young擬減持15000股,總價約20.57萬美元
2024/06/17

關聯方擬減持公告

Form144|諾瓦瓦克斯高管Filip Dubovsky擬減持13904股,總價約20萬美元
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/05/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/26

重要事件披露

Form 8-K - Current report
2024/04/15

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/15

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/03/26

重要事件披露

Form 8-K - Current report
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/28

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/22

重要事件披露

Form 8-K - Current report